Enhanced TG2 expression and/or activity, especially of nuclear TG2, has been observed in several neurodegenerative disorders, such as Alzheimer’s disease (AD), Huntington’s disease (HD), and Parkinson’s disease (PD) [115]. This evidence concerns the gene TGM2 and Parkinson disease.